About

Hybridoma technology was developed by Kohler and Milstein in 1975. Many companies are still using the same technology today to generate monoclonal antibodies. Precision Antibody has been the first CRO to introduce single hybridoma cell cloning in the generation of monoclonal antibodies, while many others were still using limited dilution technique used since 1975.

While the selection of monoclonal antibodies is still based on ELISA screening, Precision Antibody considers biophysical characterization of the antibody adds necessary information to be used in the clone selection process. Precision Antibody was the first to incorporate Biacore assay in the characterization of the antibody during this development process in 2007.

In 2010, Precision Antibody incorporated Intellicyte in our clone selection process aiming at the development of antibodies against cell surface targets. This high throughput flow-based clone screening allows us to deliver pertinent information for antibody selection to our clients quickly.

In 2015, we have incorporated Protein Simple WES in our screening process to facilitate a rapid quantitative high throughput validation of antibodies that work in IP, IHC and Western blot assays. We also offer cancer cell-line screening for target expression using Protein Simple WES with up to 45 selected human cancer cell lines.

In 2021, we are offering new innovative technologies: 1. High throughput digital SPR service allowing a large number of label-free screening and affinity measurements; 2. High throughput variable region DNA sequencing of mouse and human antibodies; 3. Total Antibody Technology (TAT) that allows all of the hybridomas to be screened against the target antigen; and 4. Fully human monoclonal antibody development technology.

We are always incorporating cutting-edge technologies offering the most advanced strategy to our customers’ antibody discovery goals and projects. Precision Antibody is always looking into the future.